Introduction Transcriptional regulatory proteins represent approximately 20% of all identified oncogenes, making them among the most attractive yet challenging targets in drug discovery. These proteins govern gene expression programs that drive cellRead More…
Heterobifunctional degraders targeting BCR-Abl, BTK, CDK9, and DAPK1 offer a strategy to bypass kinase inhibitor resistance. Explore ligand design principles. Introduction Targeted protein degradation has emerged as one of the most compellingRead More…
The human kinome, a vast landscape of over 500 protein kinases, stands as a cornerstone of cellular signaling. These enzymes, governing processes from proliferation to apoptosis, have long been a primary focusRead More…
The pharmaceutical landscape is currently witnessing a tectonic shift. For decades, the “occupancy-driven” model—where a small molecule sits in a protein’s active site to inhibit its function—has been the gold standard. However,Read More…
In the rapidly evolving landscape of modern pharmacology, we are witnessing a fundamental shift from “blocking” to “destroying.” For decades, the pharmaceutical industry relied on the occupancy-driven model—small molecules designed to sitRead More…
For decades, drug discovery has been somewhat limited by the “lock and key” paradigm. Small molecule inhibitors required a deep, well-defined pocket on the target protein’s surface to bind effectively and blockRead More…
In the vast landscape of drug discovery, a paradigm shift is underway. For decades, the “occupancy-driven” model has dominated the field—the idea that to treat a disease, a small molecule must bindRead More…
In the complex landscape of oncology, few challenges are as daunting as treating cancer that has metastasized to the brain. For patients and researchers alike, the blood-brain barrier—a protective shield that preventsRead More…
The landscape of cancer treatment is undergoing a fundamental shift, moving beyond traditional methods of protein inhibition toward a more profound and comprehensive therapeutic strategy: targeted protein degradation (TPD). This innovative approachRead More…
Endocrine therapy has long been a vital treatment option for estrogen receptor-alpha (ERα)-positive breast cancer. However, the frequent clinical problem of endocrine therapy resistance has left many patients in a difficult situation. This is particularly true whenRead More…